{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:02:49Z","timestamp":1766466169113},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.leukres.2007.05.023","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T07:18:31Z","timestamp":1184656711000},"page":"103-112","source":"Crossref","is-referenced-by-count":10,"title":["PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells"],"prefix":"10.1016","volume":"32","author":[{"given":"S.","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Canestraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pacini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Orciuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Trombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mattii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Battolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Collecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Veroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Simi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Piaggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Casini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2007.05.023_bib1","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.leukres.2007.05.023_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1006\/bbrc.2000.2909","article-title":"NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis","volume":"273","author":"Kim","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.leukres.2007.05.023_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/sj.leu.2401705","article-title":"Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells","volume":"14","author":"Kordes","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2007.05.023_bib5","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","article-title":"Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression","volume":"65","author":"Komura","year":"2005","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2007.05.023_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/10428199609074375","article-title":"Current perspective in agnogenic myeloid metaplasia","volume":"22","author":"Tefferi","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2007.05.023_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2141.1986.tb02227.x","article-title":"Multilineage expression of haemopoietic precursors with an abnormal clone in idiopathic myelofibrosis","volume":"64","author":"Sato","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10428199509054751","article-title":"TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders","volume":"20","author":"Martyre\u2019","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2007.05.023_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1365-2141.1996.4631004.x","article-title":"Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis","volume":"93","author":"Rameshwar","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.165.4.2271","article-title":"NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis","volume":"165","author":"Rameshwar","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2007.05.023_bib11","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of myelofibrosis with myeloid metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.023_bib12","first-page":"191","article-title":"Targeting proteasome inhibition in hematologic malignancies","volume":"7","author":"Hideshima","year":"2003","journal-title":"Rev Clin Exp Hematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib13","doi-asserted-by":"crossref","first-page":"17593","DOI":"10.1074\/jbc.C300076200","article-title":"JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells","volume":"278","author":"Chauhan","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2007.05.023_bib14","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1038\/sj.onc.1206734","article-title":"Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells","volume":"22","author":"Chauhan","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2007.05.023_bib15","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.023_bib16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1349-7006.2004.tb03200.x","article-title":"Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK\/c-Jun\/AP-1 signaling","volume":"95","author":"Yang","year":"2004","journal-title":"Cancer Sci"},{"key":"10.1016\/j.leukres.2007.05.023_bib17","first-page":"2638","article-title":"The proteasome inhibitor PS-341 in cancer therapy","volume":"5","author":"Teicher","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib18","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1365-2141.2003.04250.x","article-title":"Carboxy-terminal fragment of osteogeneic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis","volume":"121","author":"Fazzi","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib20","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.onc.1201747","article-title":"Activation of the wt1 Wilms\u2019 tumor suppressor gene by NF-kappaB","volume":"16","author":"Dehbi","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2007.05.023_bib21","first-page":"1005","article-title":"Nuclear factor k B is activated in myelodysplastic bone marrow cells","volume":"87","author":"Sanz","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2007.05.023_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0145-2126(94)00157-6","article-title":"Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines","volume":"19","author":"Testi","year":"1995","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.0902-4441.2003.00185.x","article-title":"Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis","volume":"72","author":"Galimberti","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib24","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.05.023_bib26","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.023_bib27","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.023_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2005.05.018","article-title":"Idiopathic myelofibrosis","volume":"42","author":"Barosi","year":"2005","journal-title":"Semin Hematol"},{"key":"10.1016\/j.leukres.2007.05.023_bib29","first-page":"M55","article-title":"The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance","volume":"1470","author":"Mayo","year":"2000","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2007.05.023_bib30","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1038\/sj.leu.2402675","article-title":"Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients","volume":"16","author":"Cilloni","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2007.05.023_bib31","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1182\/blood-2002-06-1831","article-title":"The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia","volume":"101","author":"Ogawa","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.05.023_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.leukres.2004.08.003","article-title":"Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr\/abl+CML","volume":"29","author":"Na","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.05.023_bib33","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cncr.20457","article-title":"Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation","volume":"101","author":"Cilloni","year":"2004","journal-title":"Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.leukres.2007.05.023_bib34","first-page":"245","article-title":"Characterization of differentially expressed genes in CD34+ cells from peripheral blood of idiopathic myelofibrosis patients using microarray analysis","volume":"90","author":"Guglielmelli","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2007.05.023_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/stemcells.2004-0131","article-title":"Detection of aberrant gene expression in CD34+ hematopoietic stem cells from patients with agnogenic myeloid metaplasia using oligonucleotide microarrays","volume":"23","author":"Jones","year":"2005","journal-title":"Stem Cells"},{"key":"10.1016\/j.leukres.2007.05.023_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-006-4689-y","article-title":"Tesoriere GJNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL\/caspase-8 and mitochondria-dependent pathways","volume":"11","author":"Lauricella","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.leukres.2007.05.023_bib37","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-03-0494","article-title":"Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors","volume":"10","author":"Zheng","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607002202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607002202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T03:40:54Z","timestamp":1556682054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212607002202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0145212607002202"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2007.05.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}